miR-484: A Potential Biomarker in Health and Disease

Abstract

Disorders of miR-484 expression are observed in cancer, different diseases or pathological states. There is accumulating evidence that miR-484 plays an essential role in the development as well as the regression of different diseases, and miR-484 has been reported as a key regulator of common cancer and non-cancer diseases. The miR-484 targets that have effects on inflammation, apoptosis and mitochondrial function include SMAD7, Fis1, YAP1 and BCL2L13. For cancer, identified targets include VEGFB, VEGFR2, MAP2, MMP14, HNF1A, TUSC5 and KLF12. The effects of miR-484 on these targets have been documented separately. Moreover, miR-484 is typically described as an oncosuppressor, but this claim is simplistic and one-sided. This review will combine relevant basic and clinical studies to find that miR-484 promotes tumorigenesis and metastasis in liver, prostate and lung tissues. It will provide a basis for the possible mechanisms of miR-484 in early tumor diagnosis, prognosis determination, disease assessment, and as a potential therapeutic target for tumors.

Overexpression of CENPL mRNA potentially regulated by miR-340-3p predicts the prognosis of pancreatic cancer patients

“…miRNAs widely participate in signal activation, and cell proliferation, differentiation and death [ 35 ]. miR-484 is a key factor in cancer and non-cancerous diseases, and its targets in cancer include VEGFB, VEGFR2, MAP2, MMP14, HNF1A, TUSC5, and KLF12 [ 36 ]. miR-484 was found to precipitate tumorigenesis and metastasis in liver, prostate and lung cancers [ 36 ].…”

“…miR-484 is a key factor in cancer and non-cancerous diseases, and its targets in cancer include VEGFB, VEGFR2, MAP2, MMP14, HNF1A, TUSC5, and KLF12 [ 36 ]. miR-484 was found to precipitate tumorigenesis and metastasis in liver, prostate and lung cancers [ 36 ]. Nan et al reported that in pancreatic ductal adenocarcinoma, the inhibitory effect of miR-484 on YAP was attenuated and predicted adverse patient outcomes [ 37 ].…”

“…PAAD patients with lower miR-340-3p expression have shorter survival (p < 0.05) (D), (OncoLnc). There was no significantly correlation between miR-484 expression and the survival of PAAD patients (p > 0.05, OncoLnc) (E) liver, prostate and lung cancers [36]. Nan et al reported that in pancreatic ductal adenocarcinoma, the inhibitory effect of miR-484 on YAP was attenuated and predicted adverse patient outcomes [37].…”

Non-coding RNAs in hepatocellular carcinoma: Insights into regulatory mechanisms, clinical significance, and therapeutic potential

“…When using the TNM stage system, miR-21 expression was higher in stages III and IV than in stages I and II; when using the BCLC staging system, miR-21 expression was higher in late BCLC stages C-D than in early BCLC stages 0-B ( 149 ). Another study showed that elevated miR-484 in serum could predict HCV-induced liver lesion progression and is strongly associated with shorter OS and PFS ( 189 ). In addition, increased levels of miR-122 in serum, predict a longer survival rate ( 196 ).…”

MicroRNA-484 / Akt axis in the regulation of breast cancer cells sensitivity to antitumor drugs

“…МикроРНК-484 длиной 22 нуклеотида локализована в промоторной области гена MARF1 (meiosis regulator and MRNA stability factor 1) на хромосоме 16p13.11 в человеческом геноме. Физиологические функции miR-484 у млекопитающих многогранны и включают влияние на стресс эндоплазматического ретикулума, окислительный стресс, воспаление, пролиферацию клеток и апоптоз [8].…”